Literature DB >> 1167871

Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.

S Ruddy, K F Austen, E J Goetzl.   

Abstract

Interaction of D (the activated form of D) and B, factors of the properdin pathway, with C3b (the major cleavage fragment of C3) generates a convertase, C3B, which cleaves C3 and initiates the terminal complement sequence C5-C9. A functionally analogous more stable C3 convertase, CoVFB, ir formed by substituting cobra venom factor (CoVF) for C3b. Mixtures of highly purified CoVF, B, and D were chemotactic for human neutrophil polymorphonuclear leukocytes as assessed in Boyden chambers either by microscopic enumeration of migrating cells or by counting of 51Cr-labeled cells. Control mixtures containing CoVF, B, and D, reacted in the absence of Mg++, were hemolytically inactive and devoid of chemotactic activity. Over a range of doses, the chemotactic activity of mixtures yielding CoVFB correlated with their hemolytic activity. Pretreatment of neutrophils with mixtures containing CoVFB rendered them unresponsive to subsequent chemotactic stimulation by kallikrein of C5a, indicating cross-deactivation to other chemotactic factors. Similar neutrophil deactivation occurred after exposure to a mixture of C3b, B, and D in which C3B was formed; with short incubation times and high cell concentration C3B also exhibited some chemotactic activity. The chemotactic activity of C3B and CoVFB is an example of a biologic function arising from interactions among factors of the properdin pathway per se, as distinguished from the capacity of this pathway to activate C3 and the terminal complement sequence.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1167871      PMCID: PMC301787          DOI: 10.1172/JCI107966

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

2.  The C3-activator system: an alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

3.  A method for assessing the in vitro chemotactic response of neutrophils utilizing 51cr-labeled human leukocytes.

Authors:  E J Goetzl; K F Austen
Journal:  Immunol Commun       Date:  1972

4.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

5.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

6.  A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization.

Authors:  E J Goetzl; K F Austen
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

7.  A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein.

Authors:  A P Kaplan; A B Kay; K F Austen
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

8.  Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.

Authors:  A N Theofilopoulos; V A Bokisch; F J Dixon
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

9.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.

Authors:  P A WARD; C G COCHRANE; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Modulation of human eosinophil polymorphonuclear leukocyte migration and function.

Authors:  E J Goetzl
Journal:  Am J Pathol       Date:  1976-11       Impact factor: 4.307

2.  Chemotactic responses of various differentiational stages of neutrophils from human cord and adult blood.

Authors:  A Boner; B J Zeligs; J A Bellanti
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

Review 3.  The human eosinophil: roles in host defense and tissue injury.

Authors:  P F Weller; E J Goetzl
Journal:  Am J Pathol       Date:  1980-09       Impact factor: 4.307

4.  Effects of human complement component 1 inactivator on neutrophil chemotaxis and chemotactic deactivation.

Authors:  R A Patrick; J C Hollers; D Y Liu; B H Giese; C W Smith
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

5.  Defective monocyte and polymorphonuclear leukocyte chemotaxis and clinical characteristics in atopic dermatitis.

Authors:  T Ternowitz; T Herlin
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

6.  Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.

Authors:  J O Shaw; M F Roberts; R J Ulevitch; P Henson; E A Dennis
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

7.  Endotoxin-induced selective dysfunction of rabbit polymorphonuclear leukocytes in response to endogenous chemotactic factors.

Authors:  K T Hartiala; L Langlois; I M Goldstein; J T Rosenbaum
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

8.  Effect of chemotactins released by Staphylococcus aureus and Pseudomonas aeruginosa on the murine respiratory tract.

Authors:  D O Sordelli; M C Cerquetti; A Morris Hooke; J A Bellanti
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

9.  Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes.

Authors:  A N Theofilopoulos; L H Perrin
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.